Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Nymox Corporation
Age
45–any
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Be male aged 45 or older.
Sign an informed consent form.
Be in good health.
Received NX-1207 in a previous completed study (other than NX02-0020) or received NX-1207 or placebo in a concurrent U.S. study (NX02-0017 and NX02-0018) and completed their V10 (365 day) visit.
Have Prostate Gland Volume ≥ 25 mL (25 g).
You may not be if
Surgery or minimally invasive surgical therapy (MIST) for treatment of BPH after first NX-1207 injection
Post-void residual urine volume \> 200 mL
Presence of a symptomatic median lobe of the prostate
History of use of self-catheterization for urinary retention.
Urinary retention in the previous 12 months.
Prostatitis
Urinary tract infection more than once in the past 12 months
Prostate or bladder cancer.
Prostate-Specific Antigen (PSA) ≥ 10 ng/mL
Poorly controlled diabetes
History or evidence of illness or condition that may interfere with study or endanger subject
Participation in a study of any investigational drug (other than NX-1207) or investigational device within the previous 90 days
Use of specific prescribed medications that may interfere with study or endanger subject
Clareo Health | Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)(NX02-0022)
